EGFR and neoplasm: For the patient we reported, based on the ILD which has been well controlled, the attending doctor suggested to choose furmonertinib, which, as a novel, third-generation EGFR-TKI, is safe and well tolerated in NSCLC patients with EGFR-sensitive mutations and EGFR T790M-resistant mutations to control tumor progression.